---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Phase of product development"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Phase of product development. Topics: Investigational status, Investigational new drug application, Initiation of the Himalayas-1 Phase 3 trial, Himalayas-1 registry status and dates, and 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Investigational status

> “We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our product candidates will ever obtain regulatory approval.”
> “have no products approved for commercial sale and have not generated any revenue”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

> “This presentation discusses our product candidates that are under preclinical or clinical study, and which have not yet been approved for marketing by the U.S. Food and Drug Administration.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.1-2"></a>

### Investigational new drug application

> “We filed and cleared an Investigational New Drug application (IND) with the Food and Drug Administration (FDA) for rinzimetostat in the fourth quarter of 2021.”
> “We completed a Phase 1b trial of rinzimetostat as a single-agent, in patients with advanced prostate cancer”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

<a id="topic-2.1.1-3"></a>

### Initiation of the Himalayas-1 Phase 3 trial

> “today announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone”
> “Following End-of-Phase 1 interactions with the FDA and other global health authorities, ORIC finalized the trial protocol and has initiated the Himalayas-1 global Phase 3 registrational trial.”

Source: [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

> “In July 2026, we announced that we initiated our first global Phase 3 registrational trial for rinzimetostat in combination with darolutamide, named Himalayas-1, in post-abiraterone mCRPC patients.”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

<a id="topic-2.1.1-4"></a>

### Himalayas-1 registry status and dates

| Registry field | Quoted record |
| --- | --- |
| Overall status | “Recruiting” |
| Study start (actual) | “2026-08-03” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2030-09” |

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248)

<a id="topic-2.1.1-5"></a>

### License from Mirati Therapeutics

> “On August 3, 2020, the Company entered into a license agreement (Mirati License Agreement) with Mirati. Under the Mirati License Agreement, Mirati granted the Company a worldwide, exclusive, sublicensable, royalty-free license under Mirati’s rights to certain patents and patent applications directed to certain small molecule compounds that bind to and inhibit PRC2”

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm)

> “Mirati has developed highly selective allosteric inhibitors of PRC2, including a lead candidate now designated as ORIC-944”
> “ORIC is not subject to any future milestone or royalty payment obligations to Mirati.”

Source: [ORIC Pharmaceuticals (2020)](https://oricpharma.com/news/oric-pharmaceuticals-expands-precision-oncology-pipeline-with-exclusive-worldwide-license-to-highly-selective-allosteric-prc2-inhibitors-from-mirati-therapeutics/)

<a id="topic-2.1.1-6"></a>

### Expedited program designations

No evidence found.

<a id="topic-2.1.1-7"></a>

### Regulatory status

No evidence found.

<a id="topic-2.1.1-8"></a>

### Launch

No evidence found.

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
